160 results on '"Hanna, Diana L."'
Search Results
2. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
3. Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.
4. Colorectal cancer: epigenetic alterations and their clinical implications
5. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
6. Supplementary Figure 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
7. Data from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
8. Data from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
9. Data from TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
10. Supplementary Figure 1 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
11. Supplementary Table 1, Supplementary Table 2A, Supplementary Table 2B, Supplementary Table 3, Supplementary Table 4, or Supplementary Table 5 from TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
12. Supplementary Figure 3 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
13. Supplementary Figure 4 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
14. Supplementary Table 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
15. Supplementary Table 3 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
16. Supplementary Figure 1 from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
17. Supplementary Table 1 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
18. Supplementary Table S3 from A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
19. Supplementary Table 1, Supplementary Table 2, Supplementary Table 3, or Supplementary Table 4 from Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy
20. A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.
21. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.
22. COVID‐19: Oncologic and Hematologic Considerations
23. Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
24. INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].
25. Biomolecular markers of cancer-associated thromboembolism
26. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer
27. Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma.
28. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
29. Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.
30. A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers.
31. Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis
32. Cabozantinib: An evolving therapy for hepatocellular carcinoma
33. A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.
34. A phase 1 trial of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.
35. Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.
36. Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.
37. The time to offer treatments for COVID-19
38. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
39. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib
40. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
41. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
42. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
43. THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19
44. Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
45. A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC).
46. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials
47. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib
48. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer
49. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy with Bevacizumab: Results from the TRIBE Study
50. Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.